Pros | - | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | - | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 0 Years | 7 Years | ||
Fund Size | 670 Cr | 6104 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹1000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.43% | 1.04% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 30 | 39 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (12.09%) Divi's Laboratories Ltd (5.9%) Apollo Hospitals Enterprise Ltd (5.59%) Mankind Pharma Ltd (5.51%) Cipla Ltd (5.16%) | Sun Pharmaceuticals Industries Ltd (11.69%) Dr Reddy's Laboratories Ltd (8.85%) Divi's Laboratories Ltd (8.13%) Cipla Ltd (7.54%) Aurobindo Pharma Ltd (5.71%) | ||
No of Sectors | 2 | 3 | ||
Top 3 Sectors | Health (97.14%) Financial Services (2.86%) | Health (96.53%) Basic Materials (2.35%) Financial Services (1.11%) | ||
Equity % | 93.28% | 95.89% | ||
Debt % | - | - | ||
P/E | 42.88 | 32.47 | ||
P/B | 6.56 | 4.4 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -3.43% | -2.93% | ||
3-Month Return | - | 3.39% | ||
6-Month Return | - | 17.74% | ||
1-Year Return | - | 5.35% | ||
3-Year Return | - | 29.28% | ||
5-Year Return | - | 21.81% |
Sharpe | - | 1.4 | ||
Alpha | - | 3.95 | ||
Beta | - | 0.94 | ||
Standard Deviation | - | 15.24 | ||
Information Ratio | - | 1.17 |
Description | Baroda BNP Paribas Health and Wellness Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sanjay Chawla | Sharmila D’mello,Dharmesh Kakkad |